Neonatal Abstinence Syndrome Assessment
The Finnegan score assesses withdrawal in newborns exposed to opioids. Twenty-one signs across CNS, metabolic, and GI categories guide treatment.
Did our AI summary help? Let us know.
Developed by Dr. Finnegan in 1975 Gold standard for NAS assessment Scores 8-12 = treatment threshold
Ready to run the numbers?
Why: NAS affects ~5-6 per 1,000 US births. Early identification and appropriate treatment are critical for outcomes.
How: Twenty-one signs across three categories are scored. Scores 8+ on three consecutive assessments or single 12+ indicate treatment.
Run the calculator when you are ready.
Minimal Withdrawal
Mild symptoms, score 0-7
Click to load
Mild NAS
Moderate symptoms, score 8-12
Click to load
Moderate NAS
Significant symptoms, treatment threshold
Click to load
Severe NAS
High score requiring treatment
Click to load
Sample Scenarios
CNS Disturbances
Metabolic/Vasomotor/Respiratory
GI Disturbances
For informational purposes only — not medical advice. Consult a healthcare professional before acting on results.
🏥 Health Facts
NAS affects ~5-6 per 1,000 US births
— CDC
21 signs across CNS, metabolic, GI
— Finnegan
What is the Finnegan Score?
The Finnegan Neonatal Abstinence Scoring System is a clinical tool used to assess and quantify withdrawal symptoms in newborns who were exposed to opioids (or other substances) during pregnancy. Developed by Dr. Loretta P. Finnegan in 1975, it remains the gold standard for evaluating Neonatal Abstinence Syndrome (NAS) severity and guiding treatment decisions.
Minimal
Observation only; no medication
Mild-Moderate
Treatment threshold reached
Moderate
Active pharmacotherapy needed
Severe
Intensive monitoring & treatment
Clinical Context: NAS affects approximately 5-6 per 1,000 hospital births in the US. The opioid crisis has dramatically increased NAS incidence since 2000. Early identification and appropriate treatment are critical for outcomes.
How the Finnegan Score Works
The scoring system evaluates 21 signs across three categories: Central Nervous System disturbances, Metabolic/Vasomotor/Respiratory signs, and Gastrointestinal disturbances. Each sign is weighted based on clinical significance.
Three Assessment Categories
CNS Disturbances
- • High-pitched cry
- • Sleep disturbance
- • Hyperactive reflexes
- • Tremors
- • Increased muscle tone
- • Excoriation
- • Seizures
Metabolic/Respiratory
- • Sweating
- • Fever
- • Frequent yawning
- • Mottling
- • Nasal stuffiness
- • Sneezing
- • Tachypnea
GI Disturbances
- • Excessive sucking
- • Poor feeding
- • Regurgitation/vomiting
- • Loose/watery stools
- • Weight loss concern
- • Dehydration risk
Scoring Protocol
Timing
- • Begin scoring 2 hours after birth
- • Score every 2-4 hours initially
- • Can extend to 8 hours when stable
Treatment Threshold
- • Single score ≥ 12
- • OR 3 consecutive scores ≥ 8
- • Protocol varies by institution
When to Use Finnegan Scoring
In-Utero Exposure
All newborns with known or suspected prenatal opioid exposure should be monitored with Finnegan scoring.
MAT Programs
Infants of mothers on methadone, buprenorphine, or other medication-assisted treatment for opioid use disorder.
Treatment Monitoring
Serial scoring guides medication titration and weaning in infants receiving pharmacological treatment.
NAS Treatment Approach
Non-Pharmacological
- • Swaddling and gentle handling
- • Dim lighting, reduced stimulation
- • Frequent small feedings
- • Skin-to-skin contact (rooming-in)
- • High-calorie formula if needed
- • Breastfeeding encouraged when appropriate
Pharmacological
- • First-line: Morphine or methadone
- • Adjunct: Phenobarbital for polysubstance
- • Alternative: Buprenorphine (emerging)
- • Dose titration based on scores
- • Gradual weaning over days-weeks
- • Protocol varies by institution
Common Assessment Challenges
Observer Variability
Different nurses may score the same infant differently. Regular training and competency assessments help maintain consistency.
Timing of Assessment
Scores should be done at consistent times relative to feeding. Scoring during hunger or immediately after feeding affects results.
Preterm Adjustments
Premature infants may show blunted withdrawal responses. Modified scoring or clinical judgment may be needed.
Polysubstance Exposure
Combined exposure to opioids + benzodiazepines, stimulants, or alcohol may alter presentation and treatment approach.
Documentation
Detailed documentation of observations supporting each score item is essential for treatment decisions and handoffs.
Protocol Adherence
Institutional protocols may vary in thresholds, timing, and treatment approach. Follow your unit's specific guidelines.
Substance-Specific Considerations
| Substance | Onset | Peak | Duration |
|---|---|---|---|
| Heroin/Short-acting Opioids | 8-24 hours | 48-72 hours | 4-10 days |
| Methadone | 24-72 hours | 72-96 hours | 2-3 weeks |
| Buprenorphine | 24-48 hours | 72-96 hours | 7-14 days |
| Benzodiazepines | Variable (days) | 1-2 weeks | 2-6 weeks |
Frequently Asked Questions
When does NAS onset typically occur?
Onset depends on the substance: Heroin/short-acting opioids cause symptoms within 24-48 hours. Methadone/buprenorphine may not show symptoms for 48-72 hours or longer due to longer half-lives. Monitoring should continue for at least 5-7 days.
How long does NAS treatment take?
Hospital stays for pharmacologically treated NAS average 17-25 days. Non-pharmacological treatment averages 5-7 days. Newer approaches like rooming-in and "Eat, Sleep, Console" have reduced treatment duration in some centers.
Are there alternatives to Finnegan scoring?
Yes. The "Eat, Sleep, Console" (ESC) approach focuses on three simple criteria and has shown reduced medication use and shorter hospital stays. However, Finnegan remains the gold standard and is required for research and many protocols.
What are long-term outcomes for NAS babies?
Research shows increased risk of developmental delays, learning difficulties, and behavioral issues. However, many NAS infants develop normally, especially with early intervention services. Stable home environments and ongoing support significantly improve outcomes.
Can mothers on MAT breastfeed?
Generally yes, if stable on methadone or buprenorphine, not using illicit drugs, HIV-negative, and without other contraindications. Breast milk provides minimal opioid transfer and may reduce NAS severity. AAP supports breastfeeding in appropriate MAT patients.
What is rooming-in and why is it beneficial?
Rooming-in keeps mother and infant together rather than separating for NICU care. Studies show it reduces Finnegan scores, medication use, and hospital stay. It promotes bonding and breastfeeding while supporting maternal recovery and parenting skills.
Finnegan vs. Eat, Sleep, Console (ESC)
Finnegan Scoring
- ✓ Gold standard, widely validated
- ✓ Required for research protocols
- ✓ Detailed symptom tracking
- × Complex, 21+ items to assess
- × High interobserver variability
- × May lead to over-treatment
Eat, Sleep, Console (ESC)
- ✓ Simple 3-question assessment
- ✓ Reduced medication use (50%+)
- ✓ Shorter hospital stays
- ✓ Better nursing consistency
- × Less granular data
- × Not accepted for all research
Many institutions are transitioning to ESC for clinical care while using Finnegan for research. Consult your unit's protocol for the appropriate approach.
Supporting Families
NAS care involves supporting the entire family unit. Many parents feel guilt, shame, or anxiety. Non-judgmental, supportive care improves outcomes for both infant and family.
Education
Teach parents about NAS symptoms, scoring, and treatment plan. Informed parents can partner in care decisions.
Involvement
Encourage skin-to-skin contact, feeding, and soothing techniques. Parents who participate have better bonding outcomes.
Resources
Connect families with social work, addiction services, and community resources for ongoing support after discharge.
Clinical Note
The Finnegan Score is a clinical tool that requires proper training to administer correctly. Interobserver variability can affect scores. This calculator is intended for educational purposes and clinical reference only.
Always follow your institution's specific NAS protocol for scoring intervals, treatment thresholds, and medication guidelines.
Related Calculators
CIWA-Ar Calculator
Clinical Institute Withdrawal Assessment for Alcohol, Revised (CIWA-Ar). A validated 10-item scale to assess alcohol withdrawal severity and guide treatment...
HealthAUDIT-C Calculator
The AUDIT-C (Alcohol Use Disorders Identification Test - Consumption) is a validated 3-question screening tool for hazardous alcohol use. Evidence-based...
HealthAUDIT Score Calculator
The AUDIT (Alcohol Use Disorders Identification Test) is the WHO gold-standard 10-question screening tool for hazardous drinking, harmful use, and alcohol...
HealthBAC Calculator
Calculate your Blood Alcohol Content (BAC) using the Widmark formula. Estimate intoxication level, time to sober, and receive safety recommendations for...
HealthCaffeine Calculator
Track your caffeine intake, calculate current caffeine levels using half-life decay modeling, and determine optimal sleep timing. Personalized for...
HealthCAGE Questionnaire Calculator
The CAGE questionnaire is a validated 4-question screening tool for alcohol problems. Simple yes/no questions to identify potential alcohol use disorders....
Health